Αρχειοθήκη ιστολογίου

Πέμπτη 14 Ιανουαρίου 2021

Cascade Catalytic Nanoplatform Based on “Butterfly Effect” for Enhanced Immunotherapy

xloma.fota13 shared this article with you from Inoreader
Cascade Catalytic Nanoplatform Based on

The GOD‐catalyzed glucose oxidation not only realizes tumor starvation therapy, but also provides H2O2 for IONP mediated Fenton reaction. In addition, the iron ions released from mesoporous IONP catalyzes Artemisinin for reactive oxygen species (ROS) generation. Therefore, the cascade catalytic nanoplatform generates ROS based on "the butterfly effect", enhancing immunotherapy.


Abstract

The unique tumor microenvironment (TME) characteristics such as immunosuppression impeded traditional cancer treatments. In contrast, developing cascade catalytic nanoplatforms by fully making use of substances in TME for cancer therapy may deserve full credit. Herein, a cascade catalytic nanoplatform based on glucose oxidase (GOD) modified mesoporous iron oxide nanoparticles (IONP) loaded with Artemisinin (ART) is developed, which is designed as IONP‐GOD@ART. GOD can catalyze the oxidization of glucose into gluconic acid and H2O2, which not only realizes tumor starvation therapy, but also provides H2O2 for IONP mediated Fenton reaction. Simultaneously, mesoporous IONP releases Fe2+ and Fe3+ ions in acidic TME. On the one hand, iron ions undergo Fenton reaction to generate hydroxyl radicals for chemodynamic therapy. On the other hand, the endoperoxide bridge in ART is broken in presence of Fe2+ and furt her generates reactive oxygen species (ROS) to achieve therapeutic purpose. In this sense, IONP‐GOD@ART manipulates TME characteristics and leads to "butterfly effect", which brings out a large amount of ROS for eliciting immunogenic cell death, inducing M1‐TAMs polarization, and further reprogramming immunosuppressive TME for enhanced immunotherapy. By this delicate design, the cascade catalytic nanoplatform of IONP‐GOD@ART realizes potent cancer immunotherapy for tumor regression and metastasis prevention.

View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου